Translational utility of experimental autoimmune encephalomyelitis: recent developments

Multiple sclerosis (MS) is a complex autoimmune condition with firmly established genetic and environmental components. Genome-wide association studies (GWAS) have revealed a large number of genetic polymorphisms in the vicinity of, and within, genes that associate to disease. However, the significance of these single-nucleotide polymorphisms in disease and possible mechanisms of action remain, with a few exceptions, to be established. While the animal model for MS, experimental autoimmune encephalomyelitis (EAE), has been instrumental in understanding immunity in general and mechanisms of MS disease in particular, much of the translational information gathered from the model in terms of treatment development (glatiramer acetate and natalizumab) has been extensively summarized. In this review, we would thus like to cover the work done in EAE from a GWAS perspective, highlighting the research that has addressed the role of different GWAS genes and their pathways in EAE pathogenesis. Understanding the contribution of these pathways to disease might allow for the stratification of disease subphenotypes in patients and in turn open the possibility for new and individualized treatment approaches in the future.

• Publication year

  2015

• Venue

  Journal of Inflammation Research

• Publication date

  2015-11-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2147/JIR.S76707PMID 26622189PMCID 4654535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis

  2015cited by this paper
• STAT4 controls GM-CSF production by both Th1 and Th17 cells during EAE

  2015cited by this paper
• Preferential Recruitment of Neutrophils into the Cerebellum and Brainstem Contributes to the Atypical Experimental Autoimmune Encephalomyelitis Phenotype

  2015cited by this paper
• Targeting and liposomal drug delivery to CD40L expressing T cells for treatment of autoimmune diseases.

  2015cited by this paper
• Therapeutic interference with leukocyte recirculation in multiple sclerosis

  2015cited by this paper
• FTO Obesity Variant Circuitry and Adipocyte Browning in Humans.

  2015cited by this paper
• Activation Status of Human Microglia Is Dependent on Lesion Formation Stage and Remyelination in Multiple Sclerosis

  2015cited by this paper
• CXCL13 antibody for the treatment of autoimmune disorders

  2015cited by this paper
• Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.

  2015cited by this paper
• Multiple sclerosis risk loci correlate with cervical cord atrophy and may explain the course of disability

  2015cited by this paper
• Tolerogenic dendritic cells produced by lentiviral‐mediated CD40‐ and interleukin‐23p19‐specific shRNA can ameliorate experimental autoimmune encephalomyelitis by suppressing T helper type 17 cells

  2014cited by this paper
• Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis

  2014cited by this paper
• The transcription factor IRF8 activates integrin-mediated TGF-β signaling and promotes neuroinflammation.

  2014cited by this paper
• Antibody-Mediated Inhibition of TNFR1 Attenuates Disease in a Mouse Model of Multiple Sclerosis

  2014cited by this paper
• A Multiple Sclerosis–Associated Variant of CBLB Links Genetic Risk with Type I IFN Function

  2014cited by this paper
• Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells

  2014cited by this paper
• Cbl-b: Roles in T Cell Tolerance, Proallergic T Cell Development, and Cancer Immunity.

  2014cited by this paper
• CRISPR-Cas systems for editing, regulating and targeting genomes

  2014cited by this paper
• From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development.

  2014cited by this paper
• Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants

  2014cited by this paper
• Interleukin-17 (IL-17)-induced MicroRNA 873 (miR-873) Contributes to the Pathogenesis of Experimental Autoimmune Encephalomyelitis by Targeting A20 Ubiquitin-editing Enzyme*

  2014cited by this paper
• The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis.

  2014cited by this paper
• Involvement of JAK/STAT signaling in the effect of cornel iridoid glycoside on experimental autoimmune encephalomyelitis amelioration in rats.

  2014cited by this paper
• The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

  2014influential reference
• miR-20b Suppresses Th17 Differentiation and the Pathogenesis of Experimental Autoimmune Encephalomyelitis by Targeting RORγt and STAT3

  2014cited by this paper
• The role of vitamin D in reducing cancer risk and progression

  2014cited by this paper
• Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity

  2014cited by this paper
• In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed

  2014cited by this paper
• The multiple sclerosis risk gene IL22RA2 contributes to a more severe murine autoimmune neuroinflammation

  2014cited by this paper
• Cutting Edge: The Pathogenicity of IFN-γ–Producing Th17 Cells Is Independent of T-bet

  2013cited by this paper
• Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus

  2013cited by this paper
• Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-κB- and STAT1-dependent chemokine production in astrocytes

  2013cited by this paper
• Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation

  2013cited by this paper
• Expanding roles for GILT in immunity.

  2013cited by this paper
• Embelin Suppresses Dendritic Cell Functions and Limits Autoimmune Encephalomyelitis Through the TGF-β/β-catenin and STAT3 Signaling Pathways

  2013cited by this paper
• LIGHT (TNFSF14/CD258) Is a Decisive Factor for Recovery from Experimental Autoimmune Encephalomyelitis

  2013influential reference
• Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

  2013cited by this paper
• Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity

  2013cited by this paper
• Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology.

  2013cited by this paper
• Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf.

  2013cited by this paper
• IL7Rα Contributes to Experimental Autoimmune Encephalomyelitis through Altered T Cell Responses and Nonhematopoietic Cell Lineages

  2013cited by this paper
• Paracaspase MALT1 Deficiency Protects Mice from Autoimmune-Mediated Demyelination

  2013cited by this paper
• Communication between pathogenic T cells and myeloid cells in neuroinflammatory disease.

  2013cited by this paper
• Anti-CD40 Ab- or 8-oxo-dG-enhanced Treg cells reduce development of experimental autoimmune encephalomyelitis via down-regulating migration and activation of mast cells.

  2013cited by this paper
• Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects

  2013cited by this paper
• Genetic Variation near IRF8 is Associated with Serologic and Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis

  2013cited by this paper
• Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis

  2012cited by this paper
• The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.

  2012cited by this paper
• Modelling Genetic Susceptibility to Multiple Sclerosis with Family Data

  2012cited by this paper
• Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients

  2012cited by this paper
• TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

  2012cited by this paper
• Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice

  2012cited by this paper
• JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.

  2012cited by this paper
• T cell receptor/CARMA1/NF-κB signaling controls T-helper (Th) 17 differentiation

  2012cited by this paper
• A Switch in Pathogenic Mechanism in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis in IFN-γ–Inducible Lysosomal Thiol Reductase-Free Mice

  2012cited by this paper
• Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation

  2012cited by this paper
• Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis.

  2012cited by this paper
• CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells

  2012cited by this paper
• The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF

  2011cited by this paper
• IL-7Rα confers susceptibility to experimental autoimmune encephalomyelitis

  2011cited by this paper
• Critical Role of TCF-1 in Repression of the IL-17 Gene

  2011cited by this paper
• RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation

  2011cited by this paper
• Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

  2011cited by this paper
• Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?

  2011cited by this paper
• Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.

  2011cited by this paper
• Monoclonal antibody therapy-associated neurological disorders

  2011cited by this paper
• Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions

  2011cited by this paper
• IL-7 Promotes TH1 Development and Serum IL-7 Predicts Clinical Response to Interferon-β in Multiple Sclerosis

  2011cited by this paper
• Amelioration of Experimental Autoimmune Encephalomyelitis by Plumbagin through Down-Regulation of JAK-STAT and NF-κB Signaling Pathways

  2011cited by this paper
• CCR4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function.

  2011cited by this paper
• Interleukin‐2/interleukin‐2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation

  2011cited by this paper
• Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.

  2011cited by this paper
• Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells

  2010cited by this paper
• Signaling Pathways in the Activation of Mast Cells Cocultured with Astrocytes and Colocalization of Both Cells in Experimental Allergic Encephalomyelitis

  2010cited by this paper
• Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation.

  2010cited by this paper
• Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1.

  2010cited by this paper
• Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling

  2010cited by this paper
• Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis

  2010influential reference
• Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis

  2010cited by this paper
• Regulation of Th1 and Th17 Cell Differentiation and Amelioration of Experimental Autoimmune Encephalomyelitis by Natural Product Compound Berberine

  2010cited by this paper
• CD40–CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells

  2009cited by this paper
• The AP-1 transcription factor Batf controls TH17 differentiation

  2009cited by this paper
• Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis

  2009cited by this paper
• Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses1

  2009cited by this paper
• Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20

  2009cited by this paper
• A Pivotal Role for CD40-Mediated IL-6 Production by Dendritic Cells during IL-17 Induction In Vivo1

  2009cited by this paper
• Regulatory Properties of Copolymer I in Th17 Differentiation by Altering STAT3 Phosphorylation1

  2009cited by this paper
• Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells.

  2009cited by this paper
• A Th17‐like developmental process leads to CD8+ Tc17 cells with reduced cytotoxic activity

  2009cited by this paper
• Functional Blocking Monoclonal Antibodies against IL-12p40 Homodimer Inhibit Adoptive Transfer of Experimental Allergic Encephalomyelitis 1

  2009cited by this paper
• In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression

  2009cited by this paper
• Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production.

  2009cited by this paper
• SOCS1 and SOCS3 in the control of CNS immunity.

  2009cited by this paper
• A Single Nucleotide Polymorphism in Tyk2 Controls Susceptibility to Experimental Allergic Encephalomyelitis1

  2009cited by this paper
• Stat4 Isoforms Differentially Regulate Inflammation and Demyelination in Experimental Allergic Encephalomyelitis1

  2008cited by this paper
• Loss of STAT3 in CD4+ T Cells Prevents Development of Experimental Autoimmune Diseases

  2008cited by this paper
• SOCS proteins, cytokine signalling and immune regulation

  2007cited by this paper
• Risk alleles for multiple sclerosis identified by a genomewide study.

  2007cited by this paper
• Multiple roles of TRAF3 signaling in lymphocyte function

  2007cited by this paper
• Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1

  2007cited by this paper

• CCDC134 ameliorated experimental autoimmune encephalomyelitis by suppressing Th1 and Th17 cells.

  2018cites this paper
• Translational Aspects in Drug Discovery

  2017cites this paper
• Multiple Sclerosis in Women: Vitamin D and Estrogen Synergy for Autoimmune T-Cell Regulation and Demyelinating Disease Prevention

  2017cites this paper
• Cortical Involvement in Multiple Sclerosis

  2017cites this paper
• Early Markers of Microglia Activation in Inflammatory Diseases

  2017cites this paper
• Post-translational modifications of myelin oligodendrocyte glycoprotein in CNS autoimmunity

  2016cites this paper
• Neutrophils in animal models of autoimmune disease.

  2016cites this paper
• Cytokine and chemokine alterations in tissue, CSF, and plasma in early presymptomatic phase of experimental allergic encephalomyelitis (EAE), in a rat model of multiple sclerosis

  2016cites this paper
• LIGHT (TNFSF14/CD258) Is a Decisive Factor for Recovery from Experimental Autoimmune Encephalomyelitis

  2013cites this paper